Vinge Logotype
SvenskaEnglish 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge has advised Advent International in connection with its acquisition of a minority interest in Medius
Mandate

Vinge has advised Advent International in connection with its acquisition of a minority interest in Medius

March 17, 2022 Employment and Benefits Banking and Finance M&A Commercial Agreements Intellectual Property

Medius is a global leader in AP automation, payments, sourcing and procurement. The company’s suite of products and services automate the process of receiving, handling, approving, and paying an invoice, and simplify the onboarding and managing of vendors.

Vinge’s team consisted primarily of Christina Kokko, Ulrich Ziche, Isabelle Wållgren, Eléonore Friberg and Elias Bohlin (M&A), Josefine Lanker (Banking & Finance), Mika Jordan (Commercial Agreements), Fredrika Hjelmberg and Karolina Fuhrman (IT/GDPR), Michael Montner (IP), and Veronika Garemark (Employment).

More information on the transaction can be found here. https://www.adventinternational.com/advent-international-to-acquire-minority-stake-in-spend-management-leader-medius/ 

Related

Vinge has advised Oncopeptides in connection with its rights issue

 Vinge has advised Oncopeptides AB (publ) in connection with a fully guaranteed rights issue which will provide Oncopeptides with proceeds of approximately SEK 150 million before deduction of transaction costs.
August 28, 2025

Vinge advises Main Capital and Unik in connection with the acquisition of LEB System Aktiebolag

 Vinge has advised Unik International ApS (“Unik”), a Danish Housing and Property Management software provider, in connection with the acquisition of LEB System Aktiebolag. The synergistic acquisition is expected to complement and expand Unik’s offering and has a strong strategic fit with Unik and is in line with the company’s internationalization strategy in the Nordic Property Management software market.
August 28, 2025

Vinge has advised Xspray Pharma in connection with its rights issue and debt refinancing

 Vinge has advised Xspray Pharma AB (publ) in connection with a rights issue of approximately SEK 130 million before transaction costs, with an over-allotment issue of approximately SEK 20 million, and refinancing of an existing loan.
August 28, 2025